VIRGINIA RETIREMENT SYSTEMS ET Al Sells 6,100 Shares of Tenet Healthcare Corporation $THC

VIRGINIA RETIREMENT SYSTEMS ET Al lowered its position in shares of Tenet Healthcare Corporation (NYSE:THC) by 20.7% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 23,321 shares of the company’s stock after selling 6,100 shares during the period. VIRGINIA RETIREMENT SYSTEMS ET Al’s holdings in Tenet Healthcare were worth $5,960,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of the company. V Square Quantitative Management LLC purchased a new stake in Tenet Healthcare in the 3rd quarter worth approximately $26,000. Mather Group LLC. grew its position in shares of Tenet Healthcare by 126.9% during the 3rd quarter. Mather Group LLC. now owns 118 shares of the company’s stock valued at $30,000 after purchasing an additional 66 shares in the last quarter. MADDEN SECURITIES Corp purchased a new position in shares of Tenet Healthcare during the 3rd quarter valued at $38,000. Trust Co. of Vermont bought a new position in shares of Tenet Healthcare in the second quarter worth $37,000. Finally, Fortitude Family Office LLC raised its position in shares of Tenet Healthcare by 52.1% in the third quarter. Fortitude Family Office LLC now owns 222 shares of the company’s stock worth $57,000 after buying an additional 76 shares in the last quarter. Institutional investors own 95.44% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on the company. Piper Sandler set a $308.00 price objective on Tenet Healthcare in a research note on Monday, July 27th. Cantor Fitzgerald restated an “overweight” rating on shares of Tenet Healthcare in a research note on Friday, October 2nd. BMO Capital Markets began coverage on Tenet Healthcare in a report on Tuesday, September 22nd. They issued a “market perform” rating and a $265.00 price target on the stock. Wall Street Zen upgraded Tenet Healthcare from a “buy” rating to a “strong-buy” rating in a research report on Saturday, October 17th. Finally, Stephens reissued an “overweight” rating and set a $285.00 price objective on shares of Tenet Healthcare in a report on Monday, July 27th. Eighteen equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $280.16.

Tenet Healthcare Stock Performance

Tenet Healthcare stock opened at $273.25 on Monday. Tenet Healthcare Corporation has a fifty-two week low of $157.58 and a fifty-two week high of $283.05. The company has a debt-to-equity ratio of 1.76, a quick ratio of 1.52 and a current ratio of 1.58. The stock has a market cap of $21.75 billion, a P/E ratio of 7.92, a price-to-earnings-growth ratio of 1.03 and a beta of 1.20. The firm’s fifty day moving average price is $264.85 and its 200-day moving average price is $220.34.

Tenet Healthcare (NYSE:THC) last announced its earnings results on Thursday, October 29th. The company reported $6.64 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.68 by $1.96. The company had revenue of $6.28 billion during the quarter, compared to analyst estimates of $5.49 billion. Tenet Healthcare had a net margin of 13.09% and a return on equity of 28.22%. The firm’s quarterly revenue was up 6.5% compared to the same quarter last year. During the same period in the previous year, the business earned $3.70 earnings per share. On average, equities research analysts expect that Tenet Healthcare Corporation will post 21.98 earnings per share for the current fiscal year.

Insider Transactions at Tenet Healthcare

In other news, Director Richard Mark sold 10,000 shares of the company’s stock in a transaction dated Thursday, September 10th. The stock was sold at an average price of $263.42, for a total value of $2,634,200.00. Following the completion of the transaction, the director directly owned 25,121 shares in the company, valued at approximately $6,617,373.82. This represents a 28.47% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director J. Robert Kerrey sold 12,010 shares of the stock in a transaction dated Monday, September 14th. The shares were sold at an average price of $263.72, for a total value of $3,167,277.20. Following the transaction, the director owned 4,794 shares in the company, valued at $1,264,273.68. This trade represents a 71.47% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 106,484 shares of company stock worth $28,898,063. Company insiders own 0.97% of the company’s stock.

More Tenet Healthcare News

Here are the key news stories impacting Tenet Healthcare this week:

• Positive Sentiment: Tenet reported third-quarter earnings of $6.64 per share, well above the $4.68 consensus estimate, while revenue rose 6.5% year over year to $6.28 billion versus expectations of $5.49 billion. Strong hospital performance and cost discipline drove the earnings beat. Tenet Healthcare surpasses Q3 earnings and revenue estimates
• Positive Sentiment: Management raised its 2026 financial outlook and forecast adjusted EBITDA of $5.05 billion to $5.20 billion. Conifer transition-related items are expected to contribute to results, while improving hospital margins and higher-acuity services are strengthening the business outlook. Tenet forecasts 2026 adjusted EBITDA
• Positive Sentiment: Deutsche Bank raised its price target to $320 from $260 and maintained a Buy rating, signaling increased confidence in Tenet’s earnings momentum and valuation potential. Deutsche Bank raises Tenet price target
• Neutral Sentiment: Guggenheim modestly reduced its price target to $306 from $307 but retained a Buy rating, leaving its fundamental view constructive. Guggenheim Tenet Healthcare rating
• Negative Sentiment: Investors continue to face risks from payer pressure, uninsured patients and surgery-related headwinds. Commentary also noted that the headline earnings beat included transition-related benefits, which could make the results less representative of recurring performance. Tenet high-acuity strategy and third-quarter performance

Tenet Healthcare Company Profile

Tenet Healthcare Corp. (NYSE: THC) is a diversified healthcare services company headquartered in Dallas, Texas. Through its hospital operations and outpatient platforms, the company provides a range of medical services to patients across the United States.

Tenet operates acute care and specialty hospitals, ambulatory surgery centers, imaging facilities and other outpatient care sites. Its United Surgical Partners International subsidiary is a major provider of ambulatory surgery services and partners with physicians and health systems.